Source comparison
Head-to-Head vs. Cross-Trial: The Only Fair Comparisons
This is the honesty centerpiece of the entire comparison. Because no study has ever tested BPC-157 against TB-500 in the same experiment — not in humans, and not even in the same animal model — any statement that one is “better” or “faster” than the other is i
This comparison does not assign a generated winner or score.
- This is the honesty centerpiece of the entire comparison. Because no study has ever tested BPC-157 against TB-500 in the same experiment — not in humans, and not even in the same animal model — any statement that one is “better” or “faster” than the other is inference, not measurement. The table below lays out what a fair comparison can and cannot say, grading each available comparison by the strength of its underlying design.
- BPC-157 vs TB-500, directly
- None — no head-to-head study exists
- No direct data; not established
- Any ranking is cross-trial inference, not a measured result
- BPC-157 for tendon healing
- Rat Achilles / cultured tendon fibroblasts
- Animal + in-vitro only
- Positive healing and migration signals; unconfirmed in humans[2]
- TB-500 (LKKTETQ fragment) for wounds
- db/db diabetic and aged mice, dermal wounds
- Animal only
- Accelerated dermal repair in impaired-healing mice[8]
- Thymosin beta-4 for dry eye
- Human Phase II RCTs (topical, full-length Tβ4)
- Strong design, but different molecule & indication
- Mixed primary results; significant secondary improvements[9]
- BPC-157 for inflammatory bowel disease
- Early-phase human trials (Pliva program)
- Weak (early-phase, never completed)
- Hypothesis-generating; no approval reached[5]
- Notice that the strongest-designed study in the entire pair (the human dry-eye RCTs) tests the wrong molecule for the wrong use if your interest is injectable soft-tissue recovery. That is the recurring trap of this comparison: the best evidence and the marketed use rarely line up. Researchers who stack the two compounds — discussed in our reference on the BPC-157 + TB-500 recovery blend — are combining two preclinical hypotheses, not two proven therapies.